Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$2.92
-0.07 (-2.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $249.5M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
16.2x
↓EV/EBITDA
12.4x
↑ROE
16.4%
↑Gross Margin
45.3%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.8%
FCF CAGR
+3.0%
FCF margin
11.7%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.14B · net income $376.9M · FCF $249.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.14B | $2.14B | $2.44B | $2.63B | $3.11B |
| Net Income | $376.9M | $376.9M | $232.8M | $120.3M | $-291.3M |
| EBITDA | $502.9M | $502.9M | $385.5M | $323.8M | $-71.0M |
| EPS | 0.17 | 0.17 | 0.10 | 0.05 | -0.13 |
| Gross Margin | 45.3% | 45.3% | 53.5% | 58.4% | 56.9% |
| Operating Margin | 12.6% | 12.6% | 12.0% | 9.4% | 4.4% |
| Net Margin | 17.6% | 17.6% | 9.5% | 4.6% | -9.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.00 | 0.41 | 0.89 |
| Current Ratio | 1.90 | 1.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $249.5M | $249.5M | $348.0M | $244.6M | $228.6M |
| Returns | |||||
| ROE | 16.4% | 16.4% | 11.9% | 7.2% | -17.9% |
| Valuation | |||||
| P/E | 16.22 | 16.22 | 23.23 | 44.79 | — |
| EV/EBITDA | 12.37 | 12.37 | 12.78 | 16.53 | — |
| P/B | 2.85 | 2.85 | 2.77 | 3.24 | 3.41 |
| Growth & Yield | |||||
| Revenue Growth | -12.5% | -12.5% | -7.1% | -15.5% | — |
| EPS Growth | 63.8% | 63.8% | 88.1% | 141.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.4%
EPS terminal req.
$0.26
Spread vs growth
48.4%
5Y implied EPS CAGR
13.2%
EPS terminal req.
$0.31
Spread vs growth
50.6%
10Y implied EPS CAGR
11.6%
EPS terminal req.
$0.50
Spread vs growth
52.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.9%
Start / end P/E
25.4x → 17.3x
EPS bridge
0.10 → 0.17
Residual
-20.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.